Sorry, you need to enable JavaScript to visit this website.

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

May 15, 2018
On 5/15/2018, Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa), for all indications of the reference product. Please see the full press release via the link below for further details.